Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 1, 1998, Pages 106-116

  Trocóniz, Iñaki F ^b   Naukkarinen, Tarja H ^b   Ruottinen, Hanna M ^b   Rinne, Urpo K ^b   Gordin, Ariel ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AKTIPAR; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHARMACODYNAMICS; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIPARKINSON AGENTS; CATECHOLS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0031847116     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90028-5     Document Type: Article

References (37)

1. Montastruc JL, Rascol O, Senard JM. New directions in the drug treatment of Parkinson's disease. Drugs Aging 1996;9:169-84.
2. Fahn S. An overview of novel therapies for Parkinson's disease. Exp Neurol 1997;144:21-3.
3. Cedarbaum JM. Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 1987;13:141-78.
4. Rinne UK, Mölsä P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 1979;29:1584-9.
5. Cedarbaum JM, Kutt H, McDowell FH. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988;38:533-6.
6. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanism by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
7. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating parkinsonian patients. Neurology 1987;37:940-4.
8. Fabbrini G, Mouradian MM, Juncos JL, Schlegel JJ, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms; I. Ann Neurol 1988;24:366-71.
9. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms; II. Ann Neurol 1988;24:372-8.
10. Wade LA, Katzman R. 3-O-Methyldopa inhibition of 1-dopa at the blood-brain barrier. Life Sci 1975;17:131-6.
11. Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 1995;39:39-44.
12. Olanow CW, Gauger LL, Cederbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effects in Parkinson's disease. Ann Neurol 1991;29:556-9.
13. Guttman M, Léger G, Ceberbaum JM, Reches A, Woodward W, Evans A, et al. A 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992;31:628-43.
14. Reches A, Mielke LR, Fahn S. 3-O-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 1982;32:887-8.
15. Männistö PT, Kaakkola S, Nissinen E, Linden IB, Pohto P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 1988;43:1465-71.
16. Keränen T, Gordin A, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46:151-7.
17. Nutt JG, Woodward WR, Becker RM, Stone CK, Berggren K, Carter JH et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9.
18. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-9.
19. Ruottinen H, Rinne UK. Effect of one month's treatment with peripherally-acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-33.
20. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-96.
21. Karlsson M, Wikberg T. Liquid Chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 1992;10:593-600.
22. Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y. Le test à la L-Dopa dans la maladie de Parkinson. Rev Neurol 1985;141:413-5.
23. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358-71.
24. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models; I: models for covariate effects. J Pharmacokinet Biopharm 1992;20:511-28.
25. Beal SL, Sheiner LB, editors. NONMEM users guides. San Francisco: NONMEM Project Group, University of California, San Francisco; 1992.
26. Jonsson EN, Karlsson MO. Xpose: an Splus based model building aid for population analysis with NONMEM. In: Aarons L, Balant LP, Danhof M, et al, editors. The population approach: measuring and managing variability in response, concentration and dose. Brussels: European Commission; 1997.
27. Karlsson MO, Sheiner LB. The importance of modelling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993;21:735-50.
28. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. In: D'Argenio DZ, editor. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. Vol. 2. New York: Plenum Press; 1995. p. 69-86.
29. Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:385-9.
30. Nelson MV, Berchou RC, Lewitt PA, Kareti D, Kesaree N, Schlick P, et al. Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Neuropharmacology 1989;12:91-7.
31. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43:367-71.
32. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994;44:1287-92.
33. Triggs EJ, Charles BG, Contin M, Martinelli P, Cortelli P, Riva R, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996;51:59-67.
34. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-73.
35. Nelson MV, Berchou RC, LeWitt PA, Kareti D, Galloway MP. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease. Neurology 1990;40:70-4.
36. Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 1995;29:243-56.
37. Tedroff J, Hartvig P, Bjurling P, Andersson Y, Antoni G, Långström B. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm 1991;85:11-7.